GenScript Bio Sets 15 Aug 2026 U.S. Board Meeting to Approve 1H26 Interim Results and Dividend Proposal

Bulletin Express08-05 16:55

GenScript Biotech Corporation (GenScript Bio) announced that its Board of Directors will convene on Saturday, 15 August 2026 in the United States.

The meeting’s agenda includes: 1. Reviewing and approving the unaudited interim results for the six months ended 30 June 2026. 2. Authorising publication of the interim financial statements. 3. Considering the declaration of an interim dividend, if any.

The notice, dated 5 August 2026 and signed by Chairman and Executive Director Robin Meng, confirms that any discrepancies between the English and Chinese versions of the announcement will be governed by the English text.

The Board currently comprises four executive directors and six independent non-executive directors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment